The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The efficacy and safety of momelotinib in myelofibrosis with a focus on anemia outcomes
In this video, Jowan Al-Nusair, MD, Marshall University, Huntington, WV, briefly discusses the findings of a systematic review and meta-analysis evaluating the efficacy and safety of momelotinib in myelofibrosis (MF), with a focus on anemia outcomes. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
